Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Dru... ( Deal Includes up to $100MM in License...)

HOME >> BIOLOGY >> TECHNOLOGY

Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan

Date:9/26/2007

Deal Includes up to $100MM in License Fees and Potential Milestone Payments

NEW YORK, Sept. 26 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), announced today that it entered into a licensing agreement with Japan Tobacco Inc. (JT) (TSE: 2914) and Torii Pharmaceutical Co., Ltd. (Torii) (TSE: 4551), JT's pharmaceutical business subsidiary, under which JT and Torii will hold the exclusive rights for the development and commercialization of its hyperphosphatemia drug in Japan. The drug, an iron- based phosphate binder for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end stage renal disease, is currently in phase II clinical development in the United States under the name of "Zerenex(TM)." The licensing arrangement calls for JT and Torii to pay to Keryx up to $100 million in up-front license fees and payments upon the achievement of pre-specified milestones, including up to $20 million in up- front payments and near-term milestones. In addition, upon commercialization, JT and Torii will make royalty payments to Keryx on net sales of the drug in Japan. JT and Torii will be responsible for the future development and commercialization costs in Japan.

Phosphate retention and the resulting hyperphosphatemia in patients with ESRD on dialysis are usually associated with secondary hyperparathyroidism, renal osteodystrophy, soft tissue mineralization and the progression of renal failure. ESRD patients usually require treatment with phosphate-binding agents to lower and maintain serum phosphorus at acceptable levels. There are over 300,000 dialysis patients in the United States, and even with current therapy, hyperphosphatemia persists in 70% of the dialysis popula
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related biology technology :

1. WARF enters licensing agreements for stem cell products
2. Virent enters agreement with Shell Oil unit to make hydrogen with biomass
3. Software company enters health space with RFID solutions on hold
4. Lucigen Corp. enters global licensing agreement
5. Call centers and customer service: The good, the bad, and the clueless
6. GE Healthcare enters agreement with Canadian health authority
7. Data centers: Buyers beware of over-hyped facilities
8. Data centers: Blowing smoke and raising red flags
9. Prodesse enters patent agreement with Roche
10. UW-Madison enters Kauffman grant competition
11. Applied Technology Centers to aid printing and manufacturing

Post Your Comments:

(Date:11/9/2009)...Nov. 9 CEL-SCI Corporati...neth S. Rosenthal, Professor of Immunology and Mic...e of Medicine and Pharmacy, reported on work condu...land Clinic and CEL-SCI on CEL-SCI,s LEAPS vaccine...Cbio Vaccine: "All Things Considered" Conference i...

(Date:11/8/2009)...IEW, Calif. Nov. 5, 2009 Complete Genomics, a th...day announced publication of a report in the journ...cing platform, including analysis of sequence data...s cost for these three genomes sequenced on the pr...m $8,005 for 87x coverage to $1,726 for 45x covera...

(Date:11/6/2009)..., Nov. 6 Myriant Technologies LLC ...nd manufacturer of renewable bio-chemicals, Uhde ...y provider Uhde GmbH, one of the world,s leading e... an alliance for the engineering, procurement &...c Acid plants based on renewable feedstocks. The ...

(Date:11/6/2009)...f., Nov. 6 Intarcia Therapeutics, ... 650 (DUROS® continuous delivery of exenatide...the Ninth Annual Diabetes Technology Meeting in Sa...com/cgi-bin/prnh/20050301/SFTU126LOGO ) ,, Co...CA 650 Lowers Plasma Glucose, HbA1c and Reduces We...

Breaking Biology Technology:CEL-SCI Collaborators Present Data Suggesting That LEAPS Technology Has Ability to Modify Immune Response 2 CEL-SCI Collaborators Present Data Suggesting That LEAPS Technology Has Ability to Modify Immune Response 3 Complete Genomics publishes in Science on low-cost sequencing of 3 human genomes 2 Myriant Technologies LLC, Uhde Corporation of America and Uhde GmbH Announce Alliance for Engineering, Procurement & Construction of World Scale Renewable Succinic Acid Plants 2 Myriant Technologies LLC, Uhde Corporation of America and Uhde GmbH Announce Alliance for Engineering, Procurement & Construction of World Scale Renewable Succinic Acid Plants 3 Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 2 Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 3 Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 4 Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 5

[0] CEL-SCI Collaborators Present Data Suggesting That LEAPS Technology Has Ability to Modify Immune Response [0] Complete Genomics publishes in Science on low-cost sequencing of 3 human genomes [1] Myriant Technologies LLC, Uhde Corporation of America and Uhde GmbH Announce Alliance for Engineering, Procurement & Construction of World Scale Renewable Succinic Acid Plants [0] Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting

...fficient gene transfer and high-level protein expr... Hosfield Lisa Eldridge ,Stratagene , Recombi...e delivery and,expression. We describe the AdEas...simplifies the production of such viruses. Constru...AdEasy system is a two-step process in which the d...

...,, High-quality RNA for RT-PCR using th...kit , , Karen Dolter Jeff Braman ...ermined that standard RNA purification kits are ,...PCR (RT-PCR) applications. We , tested se... and have shown , that contaminating DNA ...

...,,,, A powerful method to det..., Tanya Hosfield Cathy Chang ,Stratagene , Wi...,hybrid genes are used to detect protein-protein i...expression. This expression occurs as a result of,...tor caused by the association of,two hybrid prot...

Other Biology Technology:Generate Adenovirus Vectors in E. coli by Homologous Recombination,with the AdEasy Adenoviral Vector System 2 Generate Adenovirus Vectors in E. coli by Homologous Recombination,with the AdEasy Adenoviral Vector System 3 Generate Adenovirus Vectors in E. coli by Homologous Recombination,with the AdEasy Adenoviral Vector System 4 Generate Adenovirus Vectors in E. coli by Homologous Recombination,with the AdEasy Adenoviral Vector System 5 Generate Adenovirus Vectors in E. coli by Homologous Recombination,with the AdEasy Adenoviral Vector System 6 New Kit Generates Exceptionally Pure Total RNA for RT-PCR 2 New Kit Generates Exceptionally Pure Total RNA for RT-PCR 3 New Kit Generates Exceptionally Pure Total RNA for RT-PCR 4 New Kit Generates Exceptionally Pure Total RNA for RT-PCR 5 New Mammalian Two-Hybrid System Detects Protein-Protein Interactions 2 New Mammalian Two-Hybrid System Detects Protein-Protein Interactions 3 New Mammalian Two-Hybrid System Detects Protein-Protein Interactions 4 New Mammalian Two-Hybrid System Detects Protein-Protein Interactions 5 New Mammalian Two-Hybrid System Detects Protein-Protein Interactions 6 New Mammalian Two-Hybrid System Detects Protein-Protein Interactions 7 New Mammalian Two-Hybrid System Detects Protein-Protein Interactions 8 New Mammalian Two-Hybrid System Detects Protein-Protein Interactions 9

Generate Adenovirus Vectors in E. coli by Homologous Recombination,with the AdEasy Adenoviral Vector System New Kit Generates Exceptionally Pure Total RNA for RT-PCR New Mammalian Two-Hybrid System Detects Protein-Protein Interactions

(Date:11/9/2009)...try leaders from around the world will gather in B...ecular Targets and Cancer Therapeutics Internation...nformation on important cancer therapies in develo...eat it effectively we need a greater understanding... level," said Lewis Cantley, Ph.D., director of th...

(Date:11/8/2009)...oss of a gene through deletion of genetic material...bnormalities in learning and behavior, said a cons...icine ( www.bcm.edu ) in a report that appears onl...his research goes about 95 percent of the way to p...iduals to this gene," said Dr. Arthur L. Beaudet (...

(Date:11/6/2009)... this month of the publication of On the Origin of...ences (AIBS) is publishing open access two peer-re...ric insights into evolution. , The two articles a..., Berkeley, and James T. Costa of Western Carolina...arles Darwin," appeared in the October issue of th...

Breaking Biology News(10 mins):Developmental delay could stem from nicotinic receptor deletion 2 Emergency Nurses Association Announces Corporate Supporters for 2009 Annual Conference 58031 1 Emergency Nurses Association Announces Corporate Supporters for 2009 Annual Conference 58031 2 Upcoming trends in hematological malignancies 58028 1 Women with atrial fibrillation are at significantly higher risk of stroke and death compared to men 58025 1 Women with atrial fibrillation are at significantly higher risk of stroke and death compared to men 58025 2 Women with atrial fibrillation are at significantly higher risk of stroke and death compared to men 58025 3

[0] AACR, NCI and EORTC to host Molecular Targets and Cancer Therapeutics International Conference [0] Developmental delay could stem from nicotinic receptor deletion [0] AIBS publishes Darwin articles open access

... particularly trees, play a crucial role in sustai...s, according to a recently held workshop organised...nding provides important clues for protecting Euro...n development and climate change, which are tamper... physical and biological forces acting upon them. ...

...ber 18, 2008 The American Journal of Preventive M... 2008), will be featured at the "Changing Climate ... Leading off the event is Guest Editor Howard Frum...te change on human health. , "Climate change is a... need to understand the consequences of climate ch...

...rnationally recognized climate scientist and econo...tential role of carbon capture and sequestration i...sion of the 9th International Conference on Greenh... scientists with the Department of Energy,s Pacifi...ew findings and insights to the greenhouse gas and...

Other Biology News:Alpine rivers hold important clues for preserving biodiversity and coping with climate change 2 Alpine rivers hold important clues for preserving biodiversity and coping with climate change 3 Issues at intersection of climate change and health impact global well-being 2 Issues at intersection of climate change and health impact global well-being 3 Issues at intersection of climate change and health impact global well-being 4 PNNL leadership in carbon sequestration featured at international conference 2

Alpine rivers hold important clues for preserving biodiversity and coping with climate change Issues at intersection of climate change and health impact global well-being PNNL leadership in carbon sequestration featured at international conference

Zymoclean Gel DNA Recovery Kit from Zymo Research

Rabbit Complement from Equitech-Bio

Stat-Pack Sputolysin Reagent from Caldon Biotech, Inc.

UltraClean 15 Kit from Mo Bio Laboratories, Inc.

Biology Products:

Zymoclean Gel DNA Recovery Kit from Zymo Research Rabbit Complement from Equitech-Bio Stat-Pack Sputolysin Reagent from Caldon Biotech, Inc.UltraClean 15 Kit from Mo Bio Laboratories, Inc.

Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Dru...( Deal Includes up to $100MM in License...)